Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma

BACKGROUND: Even in the era of novel immunotherapies for multiple myeloma (MM), treatment of late‐stage relapsed/refractory (RR) patients remains challenging. The aim of our study was to analyze the efficacy and safety of the five‐drug combination pomalidomide, bortezomib, doxorubicin, dexamethasone...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Zhou, Xiang, Steinhardt, Maximilian J., Grathwohl, Denise, Meckel, Katharina, Nickel, Katharina, Leicht, Hans‐Benno, Krummenast, Franziska, Einsele, Hermann, Rasche, Leo, Kortüm, Klaus M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7433809/
https://ncbi.nlm.nih.gov/pubmed/32608149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3209
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados